Curis
Working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients.
133 employees · est. 2000 · Lexington, United States
Immuneering Corporation
Helping Cancer Patients Live Longer and Feel Better
58 employees · est. 2008 · Cambridge, United States
Curis is the older company (2000 vs 2008).
Side-by-Side Comparison
| Metric | Curis | Immuneering Corporation |
|---|---|---|
| Founded | ||
| Founded | 2000 older | 2008 |
| Headquarters | ||
| Headquarters | Lexington, United States | Cambridge, United States |
| Employees | ||
| Employees | 133 | 58 |
| Industry | ||
| Industry | Biotechnology, Health Care | Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Post Ipo Equity |
| Total Funding | ||
| Total Funding | Not tracked yet | $112.00M |
| Funding Rounds | ||
| Funding Rounds | 9 | 4 |
| Services | ||
| Services | Not tracked yet | Development of oral, once-daily cancer therapeutics, Clinical trials for novel oncology drugs, Expansion of drug indications |
| Target Customers | ||
| Target Customers | Not tracked yet | Cancer patients, Healthcare providers, Oncologists, Medical researchers, Biotechnology investors |
| Taxonomy | ||
| Taxonomy | Oncology, Drug Development, Immunology, Clinical Development, Hematology, Therapeutics, Cancer Treatment, Small Molecule Inhibitors, Monoclonal Antibodies, Precision Oncology, Signal Pathway Drug Technologies, Collaborative Research, Publicly-Traded Company, Biomolecular Research | Biopharmaceutical Company, Translational Bioinformatics, Oncology Treatments, Neuroscience Programs, Drug Development Process, Patient Outcomes, Solid Tumors, Oncologic Signaling Pathways, MEK Inhibitor, RAS Mutant Tumors, MAPK Pathway, MTOR Pathway, Translational Planning, Immunotherapy, Precision Medicine |
| Website | ||
| Website | curis.com | immuneering.com |
About Curis
Curis, a publicly-traded biotechnology company (NASDAQ: CRIS), focuses on developing first-in-class and innovative therapeutics for cancer treatment. The company has three drug candidates in development: Emavusertib (CA-4948), CI-8993, and Fimepinostat. It also collaborates with Aurigene for immuno-...
About Immuneering Corporation
Immuneering Corporation, founded in 2008, is a pioneering biopharmaceutical company headquartered in the United States. Specializing in Biotechnology and Pharmaceuticals, Immuneering's slogan, “Better Medicines Through Signaling Dynamics,” reflects its commitment to enhancing patient outcomes in can...
We will tell you when either one moves
BounceWatch watches Curis and Immuneering Corporation for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Curis and Immuneering Corporatio... — by email.
Frequently Asked Questions
Compare Curis with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Curis on 9 Nov 2024, and Immuneering Corporation on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.